Monash University is a world leader in cancer research. Our work covers the spectrum of cancer types, with particular strengths in lung, prostate, breast and colorectal cancers. This broad approach means we work across multiple faculties, institutes, hospitals and partner organisations.
Monash researchers are at the international forefront in areas such as cell signalling, structural biology, drug development, epidemiology and occupational risk factors. Emerging areas of research strength include pioneering work in cancer stem cells, medical imaging, paediatric cancer care and best practice rural clinical care.
Our research activities have a strong translational and clinical focus, but draw on a base of excellence in pure biomedical sciences. The Monash Comprehensive Cancer Consortium connects multiple strands of cancer research, creating a unique network that delivers new knowledge, new treatments and better outcomes for patients.
Cancer research capabilities at Monash are enhanced by a range of facilities and technologies, including:
- Biomedical Proteomics Facility
- High Content Cellomics Screening Facility
- FishCore Facility
- Monash Antibody Technologies Facility
- Structural Biology Facilities
- Monash Micro Imaging (MMI)
Working with industry
Monash University's established links with hospitals and other clinical care services strengthens its research capabilities. The Monash Comprehensive Cancer Consortium demonstrates and nurtures these links, and ensures research outcomes translate to better bedside care and treatment.
Major partners working with Monash University on cancer research include:
- Alfred Health
- Cabrini Health
- Eastern Health
- Peninsula Health
- Peninsula Oncology
- Prince Henry's Institute
- Southern Health
- Southern Melbourne Integrated Cancer Services
- The mechanisms of cancer
- Epidemiology, risk factors, prevention
- New therapeutics
- Imaging and radiation therapies
- Clinical trials
- Quality of care and enhanced primary care
- Supportive and palliative care